Introduction: the importance of Ca^2+^ entry for function of excitable cells {#section1-2398212818794805}
============================================================================

It has been clear from the time of Sydney Ringer, working at University College London, that calcium ions (Ca^2+^) are essential for heart muscle contraction ([@bibr100-2398212818794805]). However, the paramount importance of Na^+^ and K^+^ for the activation and inactivation underlying action potential generation led to Ca^2+^ permeation being little studied for many years. In the 1950's Paul Fatt, working at University College London with both Katz and Ginsborg, found that Ca^2+^ supports action potential-like spikes in crustacean muscle ([@bibr30-2398212818794805]; [@bibr31-2398212818794805]), and this was also found to be true in barnacle muscle ([@bibr41-2398212818794805]). When it was also identified that Ca^2+^ was essential for neurotransmitter release ([@bibr58-2398212818794805]), it became clear that calcium ion entry through membranes was key to many important processes in nerves as well as muscle. These key players in the field are pictured in [Figure 1(a)--(d)](#fig1-2398212818794805){ref-type="fig"}.

![Some key figures in the early discovery of calcium channels and their pharmacology: (a) Bernard Katz, (b) Susumu Hagiwara, (c) Paul Fatt, (d) Bernard Ginsborg (right) demonstrating equipment similar to that used to record crustacean muscle action potentials, (e) Harald Reuter and (f) Albrecht Fleckenstein. (c) is taken from a photograph (1978) by Martin Rosenberg, the Physiological Society; reproduced with permission; (a), (b) and (f) are reproduced from with permission from Richard W. Tsien ([@bibr3-2398212818794805]); (d) is reproduced with permission from Bernard Ginsborg, who died this year (1925--2018).](10.1177_2398212818794805-fig1){#fig1-2398212818794805}

Identification of multiple subtypes of calcium channel {#section2-2398212818794805}
======================================================

A major contribution to the understanding of calcium channel function then came from Harald Reuter ([Figure 1(e)](#fig1-2398212818794805){ref-type="fig"}), who showed, using microelectrodes, that calcium currents were present in voltage-clamped cardiac Purkinje fibres ([@bibr97-2398212818794805]). The advent of the gigaseal patch-clamp method for recording currents through the membrane of single cells ([@bibr44-2398212818794805]) then allowed single calcium channels to be resolved ([@bibr33-2398212818794805]).

The discovery and use of verapamil, and the 1,4-dihydropyridines (DHPs) including nifedipine, as antihypertensive drugs represented a very important advance ([@bibr34-2398212818794805]) ([Figure 1(f)](#fig1-2398212818794805){ref-type="fig"}). Their target was found to be inhibition of cardiovascular calcium channels ([@bibr63-2398212818794805]); thus, the term calcium channel blocker or antagonist was coined. Related drugs were found to have agonist effects ([@bibr104-2398212818794805]), to increase cardiac calcium conductance and prolong single channel openings ([@bibr47-2398212818794805]). Both the agonist and antagonist drugs gave researchers important tools to dissect calcium channel function in a variety of tissues.

The first suggestion that there was more than one component to calcium currents in different tissues came from the group of [@bibr42-2398212818794805], followed by evidence of low threshold Ca^2+^ spikes in mammalian central neurons ([@bibr65-2398212818794805]), and distinct low voltage-activated currents in peripheral dorsal root ganglion neurons ([@bibr12-2398212818794805]; [@bibr32-2398212818794805]; [@bibr78-2398212818794805]).

Identification of N-, P- and R-type calcium currents as distinct from L-type channels {#section3-2398212818794805}
=====================================================================================

In dorsal root ganglion (DRG) neurons, it was then found that there were three calcium current components. The DHP-sensitive current was designated L-type (for long-lasting, which also had a large singe channel conductance) and the low-voltage activated component was termed T (for transient, which also had a Tiny single channel conductance). A third component, which was high-voltage activated but DHP-insensitive, was termed N-type (neither L nor T, and also exclusively Neuronal) ([@bibr37-2398212818794805]; [@bibr80-2398212818794805]) ([Figure 2(a)](#fig2-2398212818794805){ref-type="fig"}). A blocker of this component was not long in appearing. A toxin component from the marine snail *Conus geographus*, ω-conotoxin GVIA, first thought to block both neuronal L- and N-type calcium currents ([@bibr67-2398212818794805]), was later found to be highly selective for N-type channels ([@bibr6-2398212818794805]; [@bibr90-2398212818794805]). Using this pharmacological blocker, N-type calcium currents were then shown to play a key role in neurotransmitter release ([@bibr48-2398212818794805]).

![Single calcium channels with different properties, and topology of the channels. (a) Identification of a third component of voltage-gated calcium channels (N-type) from the biophysical properties of single channel currents observed in cell-attached patches on dorsal root ganglion neurons. Redrawn from [@bibr80-2398212818794805]. TP: test potential; HP: holding potential. Reproduced with thanks to Richard W. Tsien. (b) Diagram of α~1~ subunit topology and calcium channel subunit structure, also showing α~2~δ (purple) and β (blue). ϒ~1~ is only present in skeletal muscle calcium channel complexes. S4 voltage sensors in each α~1~ domain are represented by red transmembrane segments. Yellow denotes S5 and S6 pore transmembrane segments in each domain.](10.1177_2398212818794805-fig2){#fig2-2398212818794805}

The importance of pharmacological tools in the discovery of calcium channel subtypes became even more evident when it was found that the calcium current in Purkinje neurons was not blocked by DHPs or by ω-conotoxin GVIA. This current was called P-type (for Purkinje) ([@bibr66-2398212818794805]). The same group used a polyamine toxin (FTX) from the American funnel web spider to block Purkinje cell Ca^2+^ currents, but FTX was not particularly selective for P-type channels, whereas a peptide toxin component from the same spider (ω-agatoxin IVA) was more selective, blocking fully the calcium current in Purkinje neurons ([@bibr73-2398212818794805]). This toxin also inhibited a component of the calcium current in cerebellar granule cells ([@bibr85-2398212818794805]; [@bibr96-2398212818794805]), which was initially termed Q-type as it had different biophysical properties from that in Purkinje neurons ([@bibr96-2398212818794805]); however, these are usually now called PQ currents. That study also identified an additional resistant current component in cerebellar granule cells which was designated R-type ([@bibr96-2398212818794805]), and a similar novel component was also identified in bullfrog sympathetic neurons ([@bibr28-2398212818794805]). A tarantula toxin, SNX-482, was identified to block this component ([@bibr77-2398212818794805]), but it has subsequently been found also to block other channels ([@bibr59-2398212818794805]), complicating interpretation of physiological experiments using SNX-482.

Purification and molecular identification of the calcium channel subtypes {#section4-2398212818794805}
=========================================================================

Receptors for the DHP calcium antagonists were identified using \[^3^H\]-nitrendipine to guide purification. They were found to be highly concentrated in the t-tubules of skeletal muscle ([@bibr36-2398212818794805]), where they were shown to be responsible for charge movement and excitation-contraction coupling ([@bibr101-2398212818794805]). Purification studies identified the skeletal muscle DHP receptor to be a complex of five polypeptides in approximately equal amounts, and therefore considered to be subunits. They were termed, in decreasing order of size, the α~1~, α~2~, β, ϒ and δ subunits ([@bibr51-2398212818794805]; [@bibr112-2398212818794805]). The 175 kDa α~1~ subunit was tentatively identified as the pore-forming subunit of the channel, since it bound radiolabelled DHP. The associated proteins were termed auxiliary or accessory subunits.

Peptide sequence from the purified DHP receptor protein enabled the identification of probes and subsequent cloning of the skeletal muscle calcium channel ([@bibr27-2398212818794805]; [@bibr114-2398212818794805]). The hydropathy plot indicated that it was a 24 transmembrane spanning protein, with four homologous repeated domains joined by intracellular linkers, similar to recently cloned voltage-gated Na^+^ channel ([@bibr79-2398212818794805]) ([Figure 2(b)](#fig2-2398212818794805){ref-type="fig"}). This protein was termed α~1~S (for skeletal muscle) and was indisputably shown to encode a calcium channel by injection of its cDNA into dysgenic skeletal myotubes which lack the mRNA for α~1~S ([@bibr113-2398212818794805]). This restored excitation--contraction coupling, as well as the very slow calcium current observed in native skeletal muscle.

The cardiac L-type calcium channel, termed α~1~C, was then cloned by homology with α~1~S ([@bibr71-2398212818794805]). Prior to this time, the unique permeation selectivity of the voltage-gated calcium channels for Ca^2+^ had already been attributed to high affinity Ca^2+^ binding in the pore of the channel ([@bibr46-2398212818794805]), and this was borne out by identification of key glutamate residues in the pore 'P loops' ([@bibr125-2398212818794805]), whose acidic side chains were surmised to participate in Ca (α-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid)^2+^ binding and permeation.

Several brain calcium channels were then cloned and identified to encode P- and N-type channels ([@bibr74-2398212818794805]; [@bibr107-2398212818794805]; [@bibr109-2398212818794805]). These were termed α~1~A and α~1~B, respectively. Another channel was cloned and dubbed α~1~E ([@bibr108-2398212818794805]). It was first classified as a low-voltage activated T-type channel, but it soon became clear that it did not have the expected properties, and it is now considered to encode R-type channels. Genes for three T-type channels were later cloned by Perez-Reyes and colleagues ([@bibr16-2398212818794805]; [@bibr62-2398212818794805]; [@bibr87-2398212818794805]). These were termed α~1~G, H and I. In addition, two further L-type channels were identified. The first, cloned from brain, was called α~1~D ([@bibr121-2398212818794805]) and was shown to have distinctive biophysical properties, being lower voltage-activated than α~1~C ([@bibr60-2398212818794805]; [@bibr124-2398212818794805]). Finally, a fourth L-type channel was identified because of its role in a genetic form of night blindness ([@bibr4-2398212818794805]; [@bibr111-2398212818794805]), and this was also shown to have properties distinguishing it from the other L-type channels ([@bibr61-2398212818794805]).

Following the cloning and initial study of all the calcium channel α~1~ subunits identified in the mammalian genome, a rationalised nomenclature was adopted in 2000, grouping the α~1~ subunits into Ca~V~1 (L-type), Ca~V~2 (non-L-type) and Ca~V~3 (T-type) ([@bibr29-2398212818794805]) ([Table 1](#table1-2398212818794805){ref-type="table"}). Since that time the distinctive properties of multiple splice variants of these channels have also been recognised.

###### 

Subtypes of calcium channel.

![](10.1177_2398212818794805-table1)

  Activation voltage   Functional nomenclature   Channel α~1~ subunit   Ca~V~ nomenclature   Main function
  -------------------- ------------------------- ---------------------- -------------------- -------------------------------------------------------------------------
  (High)               L                         a~1~S                  1.1                  Skeletal muscle voltage sensor
  High                 L                         a~1~C                  1.2                  Cardiac, smooth muscle function
  Medium               L                         a~1~D                  1.3                  Hearing, sino-atrial node function
  Medium               L                         a~1~F                  1.4                  Retinal neurotransmission
  High                 PQ                        a~1~A                  2.1                  Synaptic transmission in CNS, motor nerves and elsewhere
  High                 N                         a~1~B                  2.2                  Synaptic transmission in PNS (and CNS, especially early in development)
  Medium               R                         a~1~E                  2.3                  Present in some neurons and synapses
  Low                  T                         a~1~G                  3.1                  Neuronal excitability, pacemaker activity, subthreshold oscillations
  Low                  T                         a~1~H                  3.2                  
  Low                  T                         a~1~I                  3.3                  

PNS: peripheral nervous system; CNS: central nervous system.

Importance of auxiliary subunits {#section5-2398212818794805}
================================

The auxiliary β subunit from skeletal muscle was the first to be cloned ([@bibr102-2398212818794805]) ([Figure 2(b)](#fig2-2398212818794805){ref-type="fig"}). It was subsequently termed β~1a~, after three further isoforms (β~2~, β~3~ and β~4~) as well as multiple splice variants were identified by homology. β~1b~ is the non-muscle splice variant of β~1~ ([@bibr92-2398212818794805]), and β~2a~ is a palmitoylated β~2~ splice variant, giving it distinctive properties ([@bibr94-2398212818794805]). The importance of these β subunits to the expression of the Ca~V~1 and Ca~V~2 channels was clear from antisense knockdown studies in native tissues and early expression studies ([@bibr5-2398212818794805]; [@bibr94-2398212818794805]). In contrast, the Ca~V~3 channels do not appear to have any obligate auxiliary subunits.

When the auxiliary α~2~δ subunit was cloned, it was realised that α~2~ and δ are encoded by the same gene and form a pre-protein, which is then proteolytically cleaved, but the α~2~ and δ proteins remain associated by pre-formed disulphide bonding ([@bibr18-2398212818794805]; [@bibr54-2398212818794805]). Its proteolytic cleavage has recently been shown to be essential for α~2~δ function ([@bibr56-2398212818794805]). The skeletal muscle α~2~δ was subsequently termed α~2~δ-1, when three further mammalian isoforms were identified: α~2~δ-2 ([@bibr2-2398212818794805]; [@bibr40-2398212818794805]), α~2~δ-3 and α~2~δ-4 ([@bibr95-2398212818794805]). The muscle α~2~δ subunit was first described as a transmembrane protein, but they have subsequently been shown to be glycosyl-phosphatidylinositol (GPI)-anchored into the outer leaflet of the plasma membrane ([@bibr17-2398212818794805]) ([Figure 2(b)](#fig2-2398212818794805){ref-type="fig"}). The α~2~δ subunit was predicted to contain a von Willebrand factor A (VWA) domain, which was found to be essential for trafficking, both of α~2~δ itself, and for its effect on the α~1~ subunits ([@bibr11-2398212818794805]; [@bibr13-2398212818794805]; [@bibr50-2398212818794805]).

The skeletal muscle calcium channel complex also contains a ϒ subunit, now called ϒ~1~ ([@bibr112-2398212818794805]) ([Figure 2(b)](#fig2-2398212818794805){ref-type="fig"}), but ϒ is not associated with other calcium channels, and further members of this 'ϒ subunit' family are now known to be trafficking proteins that modulate the function of AMPA (α-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid) glutamate receptors, rather than voltage-gated calcium channel subunits ([@bibr117-2398212818794805]). The roles of the different calcium channel auxiliary subunits have been more extensively reviewed recently ([@bibr21-2398212818794805]).

Elucidation of physiological channel function from knockout mouse studies and genetic mutations {#section6-2398212818794805}
===============================================================================================

Several spontaneously arising mouse loss-of-function mutants were identified which gave important clues as to the function of the channel subunits. This was particularly true for Ca~V~2.1, β4 and α~2~δ-2 which are strongly expressed in cerebellum, and whose mutation produced obvious ataxias ([@bibr2-2398212818794805]; [@bibr8-2398212818794805]; [@bibr35-2398212818794805]). Subsequent targeted knockouts gave similar phenotypes. A surprise came with the knockout of Ca~V~1.3, both in mice and in a homozygous human mutation, in whom the main phenotype was deafness and sino-atrial node dysfunction ([@bibr1-2398212818794805]). Furthermore Ca~V~1.4 was identified from its role in a retinal disease ([@bibr4-2398212818794805]; [@bibr111-2398212818794805]), and the knockout mouse has a similar phenotype ([@bibr68-2398212818794805]). Knockout of Ca~V~2.2 resulted in a diminution of neuropathic pain responses, reinforcing its importance in primary afferent neurotransmission ([@bibr103-2398212818794805]). Similarly, α~2~δ-1 knockout delayed the onset of mechanical hyperalgesia following neuropathic injury ([@bibr83-2398212818794805]) and α~2~δ-3 has a role in hearing ([@bibr89-2398212818794805]), and in the central control of pain ([@bibr76-2398212818794805]).

Structural studies {#section7-2398212818794805}
==================

The first components of the calcium channel complex to be amenable to structural studies were the β subunits, which contain two conserved interacting domains (SH3 and guanylate kinase-like), the latter binding to the linker between domains I and II of the channels ([@bibr14-2398212818794805]; [@bibr81-2398212818794805]; [@bibr91-2398212818794805]; [@bibr99-2398212818794805]; [@bibr118-2398212818794805]).

The first crystal structure for a calcium-selective voltage-gated channel was obtained using a mutant form of a bacterial sodium channel homolog, Na~V~Ab, a single domain channel which forms homo-tetramers ([@bibr84-2398212818794805]). This was mutated so that the pore became Ca^2+^-selective, forming Ca~V~Ab. This structure has provided multiple insights, including confirmation of the Ca^2+^ permeation process ([@bibr115-2398212818794805]). Remarkably, this channel was sensitive to calcium channel antagonists, yielding further important insight into the binding and mechanism of action of these drugs ([@bibr116-2398212818794805]). For mammalian calcium channel complexes, although low-resolution single particle electron microscopic structures were published previously ([@bibr106-2398212818794805]; [@bibr119-2398212818794805]; [@bibr122-2398212818794805]), major advances in cryo-electron microscopy were needed before a detailed structure of the skeletal muscle calcium channel was produced, very beautifully elucidating details of the pore and the subunit arrangement ([@bibr123-2398212818794805]). GPI-anchoring of α~2~δ ([@bibr17-2398212818794805]), and interaction of the α1 subunit with the VWA and Cache domains (which have similarity to bacterial chemotaxis domains) of α~2~δ ([@bibr11-2398212818794805]; [@bibr13-2398212818794805]), were confirmed in the structure ([@bibr123-2398212818794805]).

Calcium channel modulation {#section8-2398212818794805}
==========================

Only two canonical second messenger modulation pathways will be considered here, for reasons of space: inhibitory modulation of neuronal calcium channels by G-proteins, and cyclic AMP-dependent phosphorylation, mediating enhancement of L-type channels. Many other pathways also deserve mention, including Ca^2+^-calmodulin control of Ca^2+^-dependent inactivation and facilitation of L-type and P-type channels, studied extensively by the late David Yue ([@bibr19-2398212818794805]; [@bibr88-2398212818794805]).

G-protein modulation {#section9-2398212818794805}
--------------------

Voltage-dependent activation of neuronal calcium channels is required for neurotransmitter release, and this process can be inhibited by a range of modulatory neurotransmitters coupled to seven-transmembrane receptors ([@bibr20-2398212818794805]; [@bibr55-2398212818794805]; [@bibr86-2398212818794805]), leading to the view that inhibitory modulation of the calcium channel-mediated component of the presynaptic action potential underpins receptor-mediated presynaptic inhibition ([@bibr23-2398212818794805]; [@bibr26-2398212818794805]; [@bibr53-2398212818794805]) ([Figure 3(a)](#fig3-2398212818794805){ref-type="fig"}). Modulation of neurotransmitter release was found to be mediated by a pertussis toxin-sensitive GTP-binding protein, of the G~i~/G~o~ family ([@bibr22-2398212818794805]). The inhibitory modulation of neuronal calcium currents was subsequently also identified to involve these G-proteins ([@bibr105-2398212818794805]; [@bibr49-2398212818794805]) ([Figure 3(c)](#fig3-2398212818794805){ref-type="fig"}). Using both native and cloned Ca~V~2 channels, the modulation was subsequently shown to be a direct membrane-delimited effect of Gβϒ subunits ([@bibr45-2398212818794805]; [@bibr52-2398212818794805]), mediated by the channel I-II linker ([@bibr7-2398212818794805]) and its intracellular N-terminus ([@bibr82-2398212818794805]). The characteristic voltage-dependence of the inhibition, which means that inhibition is lost with large or repeated depolarisations, was shown to require participation of the calcium channel β subunit ([@bibr70-2398212818794805]).

![Inhibitory G-protein modulation of neuronal calcium channels. (a) Action potential (prolonged by K^+^ channel blockade), recorded from dorsal root ganglion neuron, showing the control, inhibition by the GABA-B agonist baclofen (100 μM) and recovery (from Figure 7 of [@bibr23-2398212818794805]. (b) Calcium channel currents recorded from dorsal root ganglion neuron, showing inhibition by baclofen (bac, 50 μM) ([@bibr24-2398212818794805]). (c) Calcium channel currents recorded from *Xenopus laevis* oocytes injected with Ca~V~2.2/β3/α~2~δ-1 and the dopamine D2 receptor, showing inhibition by the D2 agonist quinpirole (100 nM) (replotted from [Figure 2(e)](#fig2-2398212818794805){ref-type="fig"} of [@bibr10-2398212818794805].](10.1177_2398212818794805-fig3){#fig3-2398212818794805}

Cyclic AMP-dependent phosphorylation {#section10-2398212818794805}
------------------------------------

Another key example of second messenger modulation is provided by L-type calcium channels, which are potentiated by β-adrenergic receptor activation, via a cyclic AMP-dependent mechanism ([@bibr9-2398212818794805]; [@bibr98-2398212818794805]). In heart, this effect is mediated by β1-adrenergic receptors and forms one of the main components of the fight-or-flight response. However, it has been difficult to reproduce when cloned Ca~V~1.2 calcium channels are expressed, for example, in HEK-293 cells, suggesting it is more complex than simple channel phosphorylation, and indeed, the role of the several protein kinase A substrate serines in cardiac Ca~V~1.2 function is still being determined ([@bibr64-2398212818794805]; [@bibr126-2398212818794805]). Furthermore, the response to β-adrenergic stimulation may involve a proteolytically cleaved C-terminal fragment of the endogenous Ca~V~1.2 channels ([@bibr38-2398212818794805]; [@bibr39-2398212818794805]). Perhaps surprisingly, there appears to be a somewhat different basis for the spatially restricted stimulation observed in hippocampal neurons following activation by β2-adrenergic receptors of neuronal Ca~V~1.2 channels ([@bibr93-2398212818794805]).

Future research {#section11-2398212818794805}
===============

The selective pharmacology that has been so important for dissecting out the functions of different calcium channels is still incomplete. Although a selective inhibitor of the T-type calcium channels exists ([@bibr25-2398212818794805]), it does not differentiate between the Ca~V~3 channels. Similarly, there are currently no selective inhibitors of the different Ca~V~1 channels. Such inhibitors that would be able to differentiate between these very similar channels could have important therapeutic possibilities. For example, selective inhibition of Ca~V~3.2 could be of therapeutic benefit in certain types of pain ([@bibr69-2398212818794805]), and selective inhibitors of Ca~V~1.3 have potential for therapeutic use in Parkinson's disease and other disorders ([@bibr110-2398212818794805]). Furthermore, although ω-conotoxin GVIA is a selective blocker of N-type channels and a related compound is licenced for use intrathecally in some chronic pain conditions ([@bibr72-2398212818794805]), no small molecule inhibitors of N-type channels have yet been shown to be effective in clinical trials for chronic pain.

Future challenges include a full understanding of how particular calcium channels are trafficked into precise subcellular domains, for example, how some channels are targeted to dendrites ([@bibr43-2398212818794805]), while others are directed to presynaptic active zones to mediate neurotransmitter release ([@bibr57-2398212818794805]). Furthermore, calcium channels have been found to interact, directly or indirectly, with multiple scaffolding proteins, ion channels and second messenger pathways ([@bibr75-2398212818794805]), but how these are organised and function together remains to be elucidated. Related to this, the pathways for intracellular Ca^2+^ signalling to the nucleus and the selectivity for L-type Ca^2+^ channels in neurons are still being revealed ([@bibr15-2398212818794805]; [@bibr120-2398212818794805]).
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